Moderna Therapeutics today reported a 94.5% efficacy for its COVID-19 vaccine, which doesn't need to be stored at the same ultra-cold temperatures as does a similar vaccine developed by Pfizer. It also said short-term safety concerns, such as headaches and injection site soreness, self-resolved within days, and that it could have 20 million doses available by year-end.
Axios Re:Cap speaks with Moderna chief medical officer Tal Zaks about the new data, distribution, politics, and how it was preparing for this moment even before COVID-19 was discovered.
